|
Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified |
3 Months Ended | 87 Months Ended | |
|---|---|---|---|
|
Mar. 31, 2012
|
Mar. 31, 2011
|
Mar. 31, 2012
|
|
| Grant Revenue | $ 0 | $ 650 | |
| Operating expenses: | |||
| Research and development | 3,454 | 1,574 | 64,712 |
| Acquired in-process research and development | 5,500 | ||
| Selling, general and administrative | 2,387 | 1,970 | 26,402 |
| Total operating expenses | 5,841 | 3,544 | 96,614 |
| Loss from operations | (5,841) | (3,544) | (95,964) |
| Interest income | 10 | 24 | 656 |
| Interest expense | (453) | (203) | (8,276) |
| Loss before tax benefit | (6,284) | (3,723) | (103,584) |
| Income tax benefit | 0 | 698 | |
| Net loss | $ (6,284) | $ (3,723) | $ (102,886) |
| Basic and diluted net loss per common share (in dollars per share) | $ (0.43) | $ (0.26) | |
| Weighted average basic common shares outstanding (in shares) | 14,732,582 | 14,553,748 | |
| Weighted average diluted common shares outstanding (in shares) | 14,732,582 | 14,553,748 | |